Chiesi Global Rare Diseases Seeks Ema Chmp Re-Exam Of Negative View On Elfabrio 2 Mg/Kg Q4w Dosing

Like
Comment
Favorite

Chiesi Global Rare Diseases Seeks Ema Chmp Re-Exam Of Negative View On Elfabrio 2 Mg/Kg Q4w Dosing

Reuters2025-11-20

Nov 3 (Reuters) - CHIESI GLOBAL RARE DISEASES-:
*CHIESI GLOBAL RARE DISEASES - REQUESTS RE-EXAMINATION OF NEGATIVE OPINION ISSUED BY EMA'S CHMP ON PROPOSED DOSING REGIMEN OF 2 MG/KG EVERY 4 WEEKS FOR ELFABRIO
*CHIESI GLOBAL RARE DISEASES AND PROTALIX BIOTHERAPEUTICS SEEK RE-EXAMINATION FROM THE EMA FOR THE NEGATIVE OPINION FOR ELFABRIO (PEGUNIGALSIDASE ALFA) ALTERNATIVE DOSING REGIMEN OF EVERY FOUR WEEKS IN THE EU
*CHIESI GLOBAL RARE DISEASES - EXISTING MARKETING AUTHORIZATION FOR ELFABRIO REMAINS IN EFFECT
*Further company coverage: PBDA.F
* ((Reuters.Briefs@thomsonreuters.com;))

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 03-NOV-202522:14:00.11 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2584925534?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 00:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584925534","market":"nz","top_or_hot":-1,"title":"Chiesi Global Rare Diseases Seeks Ema Chmp Re-Exam Of Negative View On Elfabrio 2 Mg/Kg Q4w Dosing","media":"Reuters","content":"<html><body>Nov 3 (Reuters) - CHIESI GLOBAL RARE DISEASES-:<br/>*CHIESI GLOBAL RARE DISEASES - REQUESTS RE-EXAMINATION OF NEGATIVE OPINION ISSUED BY EMA'S CHMP ON PROPOSED DOSING REGIMEN OF 2 MG/KG EVERY 4 WEEKS FOR ELFABRIO <br/>*CHIESI GLOBAL RARE DISEASES AND PROTALIX BIOTHERAPEUTICS SEEK RE-EXAMINATION FROM THE EMA FOR THE NEGATIVE OPINION FOR ELFABRIO (PEGUNIGALSIDASE ALFA) ALTERNATIVE DOSING REGIMEN OF EVERY FOUR WEEKS IN THE EU<br/>*CHIESI GLOBAL RARE DISEASES - EXISTING MARKETING AUTHORIZATION FOR ELFABRIO REMAINS IN EFFECT<br/>*Further company coverage: PBDA.F<br/>* ((Reuters.Briefs@thomsonreuters.com;))<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 03-NOV-202522:14:00.11 GMT</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chiesi Global Rare Diseases Seeks Ema Chmp Re-Exam Of Negative View On Elfabrio 2 Mg/Kg Q4w Dosing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChiesi Global Rare Diseases Seeks Ema Chmp Re-Exam Of Negative View On Elfabrio 2 Mg/Kg Q4w Dosing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 00:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Nov 3 (Reuters) - CHIESI GLOBAL RARE DISEASES-:<br/>*CHIESI GLOBAL RARE DISEASES - REQUESTS RE-EXAMINATION OF NEGATIVE OPINION ISSUED BY EMA'S CHMP ON PROPOSED DOSING REGIMEN OF 2 MG/KG EVERY 4 WEEKS FOR ELFABRIO <br/>*CHIESI GLOBAL RARE DISEASES AND PROTALIX BIOTHERAPEUTICS SEEK RE-EXAMINATION FROM THE EMA FOR THE NEGATIVE OPINION FOR ELFABRIO (PEGUNIGALSIDASE ALFA) ALTERNATIVE DOSING REGIMEN OF EVERY FOUR WEEKS IN THE EU<br/>*CHIESI GLOBAL RARE DISEASES - EXISTING MARKETING AUTHORIZATION FOR ELFABRIO REMAINS IN EFFECT<br/>*Further company coverage: PBDA.F<br/>* ((Reuters.Briefs@thomsonreuters.com;))<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 03-NOV-202522:14:00.11 GMT</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD1lLSpJ:1","article_id":"2584925534","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584925534","pubTimestamp":1763569669,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nov 3 (Reuters) - CHIESI GLOBAL RARE DISEASES-:*CHIESI GLOBAL RARE DISEASES - REQUESTS RE-EXAMINATION OF NEGATIVE OPINION ISSUED BY EMA'S CHMP ON PROPOSED DOSING REGIMEN OF 2 MG/KG EVERY 4 WEEKS FOR E","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PLX":"Protalix BioTherapeutics Inc"},"translate_title":"Chiesi Global罕见病寻求Ema Chmp重新审查Elfabrio 2 Mg/Kg Q4w给药的负面观点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLX":0.9},"content_text":"Nov 3 (Reuters) - CHIESI GLOBAL RARE DISEASES-:*CHIESI GLOBAL RARE DISEASES - REQUESTS RE-EXAMINATION OF NEGATIVE OPINION ISSUED BY EMA'S CHMP ON PROPOSED DOSING REGIMEN OF 2 MG/KG EVERY 4 WEEKS FOR ELFABRIO *CHIESI GLOBAL RARE DISEASES AND PROTALIX BIOTHERAPEUTICS SEEK RE-EXAMINATION FROM THE EMA FOR THE NEGATIVE OPINION FOR ELFABRIO (PEGUNIGALSIDASE ALFA) ALTERNATIVE DOSING REGIMEN OF EVERY FOUR WEEKS IN THE EU*CHIESI GLOBAL RARE DISEASES - EXISTING MARKETING AUTHORIZATION FOR ELFABRIO REMAINS IN EFFECT*Further company coverage: PBDA.F* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 03-NOV-202522:14:00.11 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}